FKBP2DRUG

Development of FKBP51-Inhibitors to treat stress-related disorders: assessment of feasibility

Coordinatore	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Germany [DE]
Totale costo	150˙000 €
EC contributo	150˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-09-01   -   2015-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Nome: Silvia Cognome: Juckoff Email: send email Telefono: +49 89 30622 474 Fax: +49 89 30622 444	DE (MUENCHEN)	hostInstitution	150˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The FK506-binding protein 51 (FKBP51) plays an important role in the human stress response. In research funded by my ERC Starting Grant I identified the molecular mechanisms of how a de-repressed FKBP51 mediates stress- and trauma-induced risk for psychiatric disorders in genetically vulnerable individuals, thus validating FKBP51 as a potential drug target for stress-related disorders. The current proof-of-concept proposal aims at providing a due diligence analysis to support the concept that the development of FKBP51-directed drugs is technically feasible and economically warranted.'